ReviewBiomarker research2026
Mitochondrial DNA mutations and intercellular mitochondrial transfer in cancer: mechanisms, biological effects, and clinical potential.
Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial biology and immune crosstalk in breast cancer: therapeutic opportunities and challenges.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Mitochondrial DNA (mtDNA) mutations are frequently detected in tumor cells and represent a distinctive aspect of cancer genomics. Common types of mtDNA alterations include single nucleotide variants, insertions and deletions, and copy number changes. These mutations often result in a range of biological effects, encompassing both in situ and ectopic mechanisms. In situ, mutant mtDNA may lead to respiratory chain dysfunction, impairing oxidative phosphorylation and shifting energy production toward glycolysis and other metabolic pathways. This metabolic reprogramming, along with altered glutamine and lipid metabolism, is frequently accompanied by reactive oxygen species accumulation, which can activate pro-tumorigenic signaling cascades and contribute to genomic instability. These changes promote cancer cell proliferation, enhance invasive and metastatic potential, and facilitate immune evasion. Moreover, through mitochondrial transfer mechanisms such as tunneling nanotubes, extracellular vesicles, cell fusion, or gap junction channels, mutant mtDNA can be transmitted to other cells, serving as an important mode of intercellular communication within tumors. This process promotes tumor progression and metastasis, regulates apoptotic pathways, facilitates immune evasion, and enhances therapeutic resistance, allowing mutant mtDNA to exert ectopic effects. Clinically, mtDNA mutations hold substantial potential in oncology, with applications spanning tumor diagnosis, disease monitoring, therapeutic resistance prediction, and prognosis assessment. Analysis of tumor tissue or circulating cell-free mtDNA provides a promising non-invasive approach for these purposes. In addition, the involvement of mtDNA mutations in regulating tumor metabolism and mediating intercellular communication underscores their value as potential therapeutic targets, making them a prominent focus of current cancer research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.